Lymphocyte proliferation to Mitogens and Antigens

Last Modified: 11/15/2019 7:31:06 AM


Client Notes: Contact Client Services for a stat pick up before you collect this specimen at 266-1500 (option 1)
Specimen Requirements: 1.0 - 20.0 mL Whole Blood in a Green Top Tube(s) - Na Heparin

Specimen Volume:
 
<3 months: 1 mL 
  3 months-5 years: 3 mL
  6-18 years: 5 mL
  18 years: 20 mL
Collection Instructions: Specimen must receive testing Laboratory (Mayo) within 24 hours of draw. 
   
Draw and send to Parkview Lab Monday thru Thursday Only,  Must be to Parkview Lab by 1pm.

Date and time of draw, ordering physician and phone number are required 

Send specimen in the original tube do not aliquot  

For serial monitoring, we recommend that specimen draws be performed at the same time of day

 


Minimum Volume: 1.0 mL Whole Blood
Transport & Storage: Temperature/Stability: 48 hours Ambient
Rejection Criteria: Hemolysis; received on weekend or holiday;
Reference Range: Viability of lymphocytes at day 0: > or =75.0% 
Maximum proliferation of anti-CD3 as % CD45: > or =19.4%
Maximum proliferation of anti-CD3 as % CD3: > or =20.3%
Maximum proliferation of anti-CD3 + anti-CD28 as % CD45: > or =37.5%
Maximum proliferation of anti-CD3 + anti-CD28 as % CD3: > or =44.6%
Maximum proliferation of anti-CD3 + IL-2 as % CD45: > or =41.7%
Maximum proliferation of anti-CD3 + IL-2 as % CD3: > or =46.2%
Methodology: Flow Cytometry
Clinical Significance: A second-level test after lymphocyte proliferation to mitogens (specifically phytohemagglutinin) has been assessed. The anti-CD3 proliferation panel is not a first-level test for assessing lymphocyte (T-cell) function 

Evaluating patients suspected of having impairment in cellular immunity

Evaluation of T-cell function in patients with primary immunodeficiencies, either cellular (DiGeorge syndrome, T-negative severe combined immunodeficiency [SCID], etc) or combined T- and B-cell immunodeficiencies (T- and B-negative SCID, Wiskott Aldrich syndrome, ataxia telangiectasia, common variable immunodeficiency, among others) where T-cell function may be impaired

Evaluation of T-cell function in patients with secondary immunodeficiency, either disease related or iatrogenic

Evaluation of recovery of T-cell function and competence following bone marrow transplantation or hematopoietic stem cell transplantation 

Evaluation of T-cell function in patients receiving immunosuppressive or immunomodulatory therapy 

Evaluation of T-cell function in the context of identifying neutralizing antibodies in patients receiving therapeutic anti-CD3 antibody immunosuppression for solid organ transplantation or autoimmune diseases, such as type 1 diabetes
Documentation: When interpreting results it should be kept in mind that the range of lymphocyte proliferative responses observed in healthy, immunologically competent individuals is large. The reference ranges provided (based on healthy donors) will be helpful in ascertaining the magnitude of the patient response.
Custom Panel: No

PRODUCTION SCHEDULE

Turn Around Time: 5 to 8 days
Days Performed: Monday, Tuesday, Wednesday, Thursday, Friday
Sites Performed: Mayo Laboratory
PHL Test Code: MSOT
EPIC Test Code: MISC
Send Out Test Code: LPA3P
Alternate Test Names: Anti-CD3 costimulation with anti-CD28; Anti-CD3 costimulation with IL-2; Assessment of T cell function; Lymphocyte Proliferation to Anti-CD3/Anti-CD28 and; Lymphocyte proliferation to Mitogens and Antigens ; Lymphocyte Proliferation, aCD3; Mitogenic stimulation with anti-CD3
CPT Coding: 86353 x 3

Go back to the top of the page.